AMSBIO has implemented a program of investment to support the students at Penn State Lehigh Valley, part of Pennsylvania State University, in their transformative Course-based Undergraduate Research Experience (CURE) program.
The CURE program, led by Dr. Jacqueline McLaughlin, allows students to dive into real-world research projects that tackle critical challenges in health and medicine. This semester’s focus is on exploring the endothelial glycocalyx—a sugar-rich layer vital for cardiovascular health.
In this project, students analysed how various basement…
The European Partnership for Personalised Medicine introduces two exciting opportunities for start-ups, researchers, and early-stage teams working on cutting-edge solutions in personalized medicine. These programmes aim to accelerate the development, validation, and market readiness of transformative innovations that enhance patient care.
Fast Track Validation Programme
Designed to address a critical bottleneck in personalized medicine development, this programme supports validation studies to elevate projects to higher technological and market readiness levels.
Who Can Apply? …
Read eNews for December here. Featuring:
✅ Tony Jones, CEO, One Nucleus - Tis the Season to be Jolly!✅ Key Dates for Your 2025 Diary by Alicia Gailliez, Business Development Manager, One Nucleus✅ Reflections on Genesis 2024✅ One Nucleus Engagement in JPM Week 2025 by Tony Jones, One Nucleus✅ Memes Meet Microbes: Spreading Awareness About Antimicrobial Resistance by CSIRO✅ A Decade of Innovation, a Decade to Come - China’s Biopharmaceutical Innovation by Clarivate
Inaphaea BioLabs, the translational contract research organisation based at MediCity Nottingham, has announced the promotion of Melissa Barr to Head of Scientific Operations.
Melissa joined Inaphaea in 2023 as Lead Scientist. Since then, she has played an instrumental role in delivering preclinical drug discovery projects across oncology and women’s health, as well as leading a team of scientists on-site.
Spun out from ValiRx PLC, Inaphaea offers cell-based assays specialising in oncology. Its aim is to improve the translation of early drug discovery projects towards the clinic.
Commenting…
A lack of access to capital, particularly proof-of-concept funding, is stifling growth in the UK’s university spinout sector, according to a recent survey conducted by Symbiosis IP, a part of professional services group Gateley.
Described by one respondent as a “broken funding model”, the sector’s lack of funding and difficulty securing much-needed investment capital, particularly outside of the South East, are two of the most urgent issues facing the university spinout sector.
Respondents also noted a lack of access to the senior management and professional services outside of the ‘Golden…
AMSBIO announce a new range of Synthetic Nanodiscs that enable preparation of multi-pass transmembrane proteins in their active form, revolutionizing the future of membrane protein research and drug development. Membrane Proteins account for more than 60% of all FDA-approved drug targets and 90% of antibody-based drug targets. Many traditional sample preparation methods struggle with challenges in obtaining water-soluble and bioactive forms of multi-pass transmembrane proteins.
Commonly, detergent has been widely used to produce multi-pass transmembrane proteins…
Recent top global hires for large-cap, mid-cap, and public companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech in the second half of 2024.CEO/ C-suite/ BoardCEO, Medtech (publicly listed), APACCEO, Life science tools (publicly listed), NordicsPresident Life Sciences, Specialty chemicals (large-cap), UK & IrelandChief Financial Officer Biotech (publicly listed), USChief Financial Officer, Biopharma/ drug delivery (publicly listed), UK & IrelandChief of Staff , Biopharma (publicly listed), EuropeChair, Mental health pharma (publicly listed…
Cancer Research Horizons, the innovation arm of Cancer Research UK, is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme.
Diamond Light Source accelerates electrons to near light speed, producing bright light that is directed into research instruments known as beamlines. Cancer Research Horizons and its drug discovery site at Newcastle University have already been using Diamond’s beamlines and XChem facility for fragment-based screening, a powerful approach to identify chemical entities that can be developed…
Cambridge, UK: o2h discovery is pleased to announce the launch of o2h Biology Match Funding award, a unique programme aimed at accelerating drug discovery research by offering to match fund 50% of the cost for biology research projects up to $65K/£50K in value. This initiative presents an exciting opportunity for biotechs of all sizes and pharma to achieve key scientific milestones, helping to advance their drug discovery programmes.The o2h Biology Match Funding programme not only supports your biology project by matching up to 50% cost but also enables participants to tap into o2h’s vast…
03 December 2024, London - A message from Dr Rich Ferrie – CEO, LBIC
LBIC is evolving. A lot has changed since we opened as London’s first bio-incubator over 24 years ago.
Today, we’re at a pivotal moment in our history, entering a new phase of growth as we expand into the Apex Building and continue to evolve within the dynamic life sciences landscape.
As part of this evolution, we’re excited to reveal our refreshed brand identity, doubling down our short-form name ‘LBIC,’ which has been widely recognised across the sector for years. Our fresh new look reflects the energy and growth of our…